File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarrays

TitleGenome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarrays
Authors
KeywordsAllelic imbalance
High-density single-nucleotide polymorphism microarrays
Loss of heterozygosity
Renal cell carcinoma
Issue Date2006
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinbiochem
Citation
Clinical Biochemistry, 2006, v. 39 n. 3, p. 187-190 How to Cite?
AbstractObjective: Renal cell carcinoma (RCC) appears in both a sporadic form and a hereditary form. Eighty-five percent of sporadic RCCs are of the clear-cell histologic type. The cytogenetic analysis of RCCs has revealed several recurring sites of chromosomal aberrations (non-disjunction, deletion or mitotic recombination) including segments of loss of heterozygosity (LOH) identifiable by polymorphic markers. In this pilot study, we performed a comprehensive genome-wide scan to identify LOH sites of RCCs in three Chinese patients using high-density single-nucleotide polymorphism microarrays (HuSNP arrays). Design and methods: Three sporadic clear-cell RCCs specimens were diagnosed histologically. Tumor genomic DNA was extracted from paraffin-embedded sections after microdissection to avoid gross contamination by non-tumor cells. Germline DNA was obtained from paired normal adjacent tissues. Affymetrix HuSNP mapping assay was performed according to the manufacturer's instructions. Results: Using high-density single-nucleotide polymorphism microarrays, we were able to identify the previously described and new LOH sites in RCCs of the three Chinese patients. Conclusion: The high-density single-nucleotide polymorphism microarrays and assays offer significant operating cost benefits in sample preparation, processing, and data analysis for identification of LOH sites in cancer samples. In contrast to the typical microsatellite genotyping strategy, the entire genome scan is completed in one experiment taking less than 2 days. © 2006 The Canadian Society of Clinical Chemists. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/148457
ISSN
2021 Impact Factor: 3.625
2020 SCImago Journal Rankings: 0.756
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, CWen_US
dc.contributor.authorTo, KFen_US
dc.contributor.authorTong, SFen_US
dc.date.accessioned2012-05-29T06:13:05Z-
dc.date.available2012-05-29T06:13:05Z-
dc.date.issued2006en_US
dc.identifier.citationClinical Biochemistry, 2006, v. 39 n. 3, p. 187-190en_US
dc.identifier.issn0009-9120en_US
dc.identifier.urihttp://hdl.handle.net/10722/148457-
dc.description.abstractObjective: Renal cell carcinoma (RCC) appears in both a sporadic form and a hereditary form. Eighty-five percent of sporadic RCCs are of the clear-cell histologic type. The cytogenetic analysis of RCCs has revealed several recurring sites of chromosomal aberrations (non-disjunction, deletion or mitotic recombination) including segments of loss of heterozygosity (LOH) identifiable by polymorphic markers. In this pilot study, we performed a comprehensive genome-wide scan to identify LOH sites of RCCs in three Chinese patients using high-density single-nucleotide polymorphism microarrays (HuSNP arrays). Design and methods: Three sporadic clear-cell RCCs specimens were diagnosed histologically. Tumor genomic DNA was extracted from paraffin-embedded sections after microdissection to avoid gross contamination by non-tumor cells. Germline DNA was obtained from paired normal adjacent tissues. Affymetrix HuSNP mapping assay was performed according to the manufacturer's instructions. Results: Using high-density single-nucleotide polymorphism microarrays, we were able to identify the previously described and new LOH sites in RCCs of the three Chinese patients. Conclusion: The high-density single-nucleotide polymorphism microarrays and assays offer significant operating cost benefits in sample preparation, processing, and data analysis for identification of LOH sites in cancer samples. In contrast to the typical microsatellite genotyping strategy, the entire genome scan is completed in one experiment taking less than 2 days. © 2006 The Canadian Society of Clinical Chemists. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinbiochemen_US
dc.relation.ispartofClinical Biochemistryen_US
dc.subjectAllelic imbalance-
dc.subjectHigh-density single-nucleotide polymorphism microarrays-
dc.subjectLoss of heterozygosity-
dc.subjectRenal cell carcinoma-
dc.subject.meshAllelic Imbalance - Geneticsen_US
dc.subject.meshCarcinoma, Renal Cell - Geneticsen_US
dc.subject.meshChromosomes, Human - Geneticsen_US
dc.subject.meshGenetic Markersen_US
dc.subject.meshGenome, Human - Geneticsen_US
dc.subject.meshHumansen_US
dc.subject.meshOligonucleotide Array Sequence Analysisen_US
dc.subject.meshPolymorphism, Single Nucleotide - Geneticsen_US
dc.titleGenome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarraysen_US
dc.typeArticleen_US
dc.identifier.emailLam, CW:ching-wanlam@pathology.hku.hken_US
dc.identifier.authorityLam, CW=rp00260en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s10554-005-9054-7en_US
dc.identifier.pmid16513104-
dc.identifier.scopuseid_2-s2.0-33644962095en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644962095&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume39en_US
dc.identifier.issue3en_US
dc.identifier.spage187en_US
dc.identifier.epage190en_US
dc.identifier.isiWOS:000236782700010-
dc.publisher.placeUnited Statesen_US
dc.identifier.issnl0009-9120-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats